A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

Stopped study ended prior enrollment of the first patient because of unexpected issues in the manufacturing process prevented production of adequate clinical batches

Conditions

• Multiple Sclerosis, Relapsing-Remitting

Interventions

• BIOLOGICAL: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope

Sponsor

Imcyse SA